Neurol. pro Praxi, 2007; 3: 168-170

Využitie botulotoxínu v terapii sialorrhei u Parkinsonovej choroby

MUDr. Ivica Husárová2, MUDr. Marek Baláž1, doc. MUDr. Martin Bareš, Ph.D.2
1 Centrum pro abnormální pohyby a parkinsonismus, I. neurologická klinika LF MU, FN u sv. Anny, Brno
2 I. neurologická klinika LF MU a FN u sv. Anny Brno

Sialorrhea je častým symptómom u Parkinsonovej choroby, vyskytuje sa takmer u 75 % pacientov. Cieľom našej retrospektívnej štúdie u pacientov s Parkinsonovou chorobou so sialorrheou bolo objektivizovať efekt aplikácie botulotoxinu A do slinných žliaz. V súbore 12 pacientov s Parkinsonovou chorobou, u ktorých bola sialorhea významným subjektivným príznakom, bola zahájená terapia botulotoxínom A. Efekt aplikácie botulotoxínu bol hodnotený škálou Unified Parkinson´s Disease Rating Scale – (UPDRS, časť 2, položka 2 a škálou Clinical Global Impression (CGI). Priemerná dávka botulotoxinu A na jednu aplikáciu bola 82,5 MU ± 33,87. Priemerná dĺžka terapeutického efektu bola 10 týždňov. 56,6 % pacientov dosiahlo CGI skóre 5, 21,7 % pacientov dosiahlo skóre 1 a ďalších 21,7 % pacientov skóre 9. Neboli zaznamenané žiadne vedľajšie účinky. Výsledky našej práce potvrdili efektivitu a bezpečnosť podania botulotoxínu pri sialorrhei u pacientov s Parkinsonovou chorobou.

Keywords: Parkinsonova choroba, sialorhea, botulotoxin A

Published: August 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husárová I, Baláž M, Bareš M. Využitie botulotoxínu v terapii sialorrhei u Parkinsonovej choroby. Neurol. praxi. 2007;8(3):168-170.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bareš M. Parkinsonova nemoc - diagnostika, klinické příznaky. Neurologie pro praxi 2001; 2, 1: 22-25.
    2. Bareš M. Pozdní komplikace Parkinsonovy nemoci - klinické projevy, léčba. Praktický lékař 2002; 82 (5): 280-283.
    3. Dogu O et al. Ultrasound - guided versus blind intraparotid injections of botulinum toxin-A for treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004, 106: 93-96. Go to original source... Go to PubMed...
    4. Glickman S and Deaney CN. Treatment of relative sialorrhoea with botulinum toxin type A: description and rationale for an injection procedure with case report. European Journal of Neurology 2001, 8: 567-571. Go to original source... Go to PubMed...
    5. Jongerius PH, van den Hoogen FJ, van Limbeek J. et al. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 2004; 114: 620-627. Go to original source... Go to PubMed...
    6. Kaňovský P. Botulotoxin a jeho role v léčbě neurologických onemocnění, Neurologie pro praxi 2001, 1: 43-46.
    7. Lagalla G, Millevolte M, Capecci M. et al. Botulinum Toxin Type A for Drooling in Parkinson's Disease: A Double-Blind, Randomized, Placebo-Controlled Study. Mov Disord 2006, 5: 704-706. Go to original source... Go to PubMed...
    8. Mancini F, Zangaglia R, Cristina S et al. Double blind placebo - controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003, 18: 685-688. Go to original source... Go to PubMed...
    9. Naver H, Aquilonius SM. The treamtent of focal hyperhidrosis with botulotoxinum. Eur J Neurol 1997; 4 (suppl 2): 75-79.
    10. Ondo WG, Hunter C, Moore W. A double-blind placebo controlled trial of botulinum toxin B for sialorrhea in Parkinson's diesease. Neurology 2004; 62: 37-40. Go to original source... Go to PubMed...
    11. Růžička E, Roth J, Kaňovský P. et al. Parkinsonova nemoc a parkinsonské syndromy, Galén, Praha 2000: 71.
    12. Tan EK. Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations, Eur J Neurol 2006, 13: 60-64. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.